Nuclear factor-κB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma

Human Pathology

Volumn 39, Issue 7, 2008, Pages 994-1001

  Gallel, Pilar ^a   Pallares, Judit ^a   Dolcet, Xavier ^a   Llobet, David ^a   Eritja, Nuria ^a   Santacana, Maria ^a   Yeramian, Andre ^a   Palomar Asenjo, Victor ^a   Lagarda, Helena ^b   Mauricio, Didac ^a   Encinas, Mario ^a   Matias Guiu, Xavier ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Antibodies; Medullary thyroid carcinoma; Molecular pathology; NF B; RET; Tissue microarray

Indexed keywords

CYCLIN D1; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARAFFIN; PROTEIN BCL XL; PROTEIN P50; PROTEIN P52; PROTEIN P56; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELB; CARRIER PROTEIN; HSAJ2425 PROTEIN, HUMAN; PROTEIN BCL X; PROTEIN RET; RET PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CELL LINE; EXON; GENE MUTATION; GENETIC TRANSFECTION; GERM LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; RETROVIRUS INFECTION; SOMATIC MUTATION; STATISTICAL SIGNIFICANCE; THYROID MEDULLARY CARCINOMA; TISSUE MICROARRAY; WILD TYPE; GENETICS; MEDULLARY CARCINOMA; METABOLISM; MUTATION; PATHOLOGY; RNA INTERFERENCE; THYROID TUMOR; TUMOR CELL LINE;

BCL-X PROTEIN; CARCINOMA, MEDULLARY; CARRIER PROTEINS; CELL LINE, TUMOR; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-RET; RNA INTERFERENCE; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 45249108658     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.11.015     Document Type: Article

References (34)

1. Dolcet X., Llobet D., Pallares J., and Matias-Guiu X. NF-kappa B in development and progression of human cancer. Virchows Arch 446 (2005) 475-482
2. Komminoth P., Kunz E.K., Matias-Guiu X., et al. Analysis of ret proto-oncogene point mutations allows for the discrimination of sporadic and inherited medullary thyroid carcinoma. Cancer 76 (1995) 479-489
3. Marsh D.J., Mulligan L.M., and Eng C. Ret proto-oncogene mutations in multiple endocrine type 2 and medullary thyroid carcinoma. Horm Res 47 (1997) 168-178
4. Marsh D.J., Learoyd D.L., and Andrew S.D. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 44 (1996) 249-257
5. Matias-Guiu X., Lagarda E., Calaf M., et al. Identification of a novel somatic mutation in the ret proto-oncogene in a patient with sporadic medullary thyroid carcinoma. Human Mutation 9 (1997) 476
6. Bugalho M.J., Frade J.P., Santos J.R., Limbert E., and Sobrinho L. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain. Eur J Endocrinol. 136 (1997) 423-426
7. Chiefari E., Russo D., Giuffrida D., et al. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. J Endocrinol Invest. 21 (1998) 358-364
8. Vasko V.V., and Saji M. Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Curr Opin Oncol 19 (2007) 11-17
9. Cranston A., Carniti C., Martin S., et al. A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation. Mol Endocrinol 20 (2006) 1633-1643
10. Bongarzone I., Vigano E., Alberti L., et al. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein. Oncogene 18 (1999) 4833-4838
11. Kjaer S., Kurokawa K., Perrinjaquet M., Abrescia C., and Ibáñez C.F. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations. Oncogene 25 (2006) 7086-7095
12. Gujral T.S., Singh V.K., Jia Z., and Mulligan L.M. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res 66 (2006) 0741-0749
13. Santoro M., Melillo R.M., Carlomagno F., Fusco A., and Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 963 (2002) 116-121
14. Knowles P.P., Murray-Rust J., Kjaer S., et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281 (2006) 33577-33587
15. Frêche B., Guillaumot P., and Charmetant J. Inducible dimerization of RET reveals a specific AKT deregulation in oncogenic signaling. J Biol Chem 280 (2005) 36584-36591
16. De Vita G., Melillo R.M., Carlomagno F., et al. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res 6037 (2000) 27-31
17. Chiariello M., Visconti R., Carlomagno F., et al. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 16 (1998) 2435-2445
18. Plaza Menacho I., Koster R., van der Sloot A.M., et al. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 65 (2005) 1729-1737
19. Plaza-Menacho I., van der Sluis T., Hollema H., et al. Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. J Biol Chem 282 (2007) 6415-6424
20. Segouffin-Cariou C., and Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 27 (2000) 3568-3576
21. Ludwig L., Kessler H., Wagner M., et al. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 61 (2001) 4526-4535
22. Pallares J., Martinez-Guitarte J.L., Dolcet X., et al. Abnormalities in nf-kb family and related proteins in endometrial carcinoma. a tissue microarray study. J Pathol 13 (2004) 569-577
23. Matias-Guiu X., Machin P., Pons C., Lagarda E., De Leiva A., and Prat J. Sustentacular cells occur frequently in the familial form of medullary thyroid carcinoma. J Pathol 184 (1998) 420-423
24. Komminoth P., Muletta-Feurer S., Saremaslani P., et al. Molecular diagnosis of multiple endocrine neoplasia (MEN) in paraffin-embedded specimens. Endocr Pathol 6 (1995) 267-278
25. Alvores-Saavedra J., LiVolsi V.A., and Williams E.D. Medullary carcinoma. Sem Diagn Pathol 2 (1985) 137-146
26. Papotti M., Sambataro D., Pecchioni C., and Bussolati G. The pathology of medullary thyroid carcinoma of the thyroid: review of the literature and personal experience of 62 cases. Endocr Pathol 7 (1996) 1-20
27. Wang W., Johansson H., Bergholm U., Wilander E., and Grimelius L. Apoptosis and expression of the proto-oncogenes bcl-2 and p53 and the proliferation factor Ki-67 in human medullary thyroid carcinoma. Endocr Pathol 7 (1996) 37-45
28. Sariola H., and Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci 116 (2003) 3855-3862
29. Irmler M., Thome M., Hahne M., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
30. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 45 (2006) 355-361
31. Pacifico F., Mauro C., Barone C., et al. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 279 (2004) 54610-54619
32. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., and Balwin Jr. A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Clell Biol 9 (1999) 5785-5799
33. Cogswell P.C., Gutridge D.C., Funkhouser W.K., and Baldwin Jr. A.S. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and Bcl-3. Oncogene 19 (2000) 1123-1131
34. Cao Y., and Karin M. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 8 (2003) 215-223